Stockreport

Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations on Wednesda...

Protara Therapeutics, Inc.  (TARA) 
PDF NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment o [Read more]